Alemtuzumab Clearance, Lymphocyte Count, and T Cell Chimerism After Hematopoietic Stem Cell Transplant in Sickle Cell Disease

Investigators examined the pharmacokinetics and pharmacodynamics of alemtuzumab in adults with sickle cell disease who received a matched related donor hematopoietic stem cell transplant and determined if the clearance of alemtuzumab affected transplant outcomes.